RESUMEDOCS

CONFIDENTIAL CLIENT SAMPLE

Currently serving as Medical Director and Principal Investigator at Nucleus Network, contributing to the clinical and operational leadership of early-phase programs and more than 70 first-in-human studies involving small molecules, biologics, siRNA, mRNA, antibodies, and vaccines. Experienced in dose-escalation decision-making, safety review processes, PK/PD interpretation, protocol feasibility assessment, and clinical trial execution within highly regulated environments.

Collaborates closely with biotech and pharmaceutical sponsors across protocol review, feasibility evaluation, and early clinical development activities, bridging scientific and clinical perspectives to support successful study delivery. Combines strong scientific credentials with leadership experience across multidisciplinary clinical and research teams.

Supported by a PhD in Neuroscience, Fellowship of the Faculty of Pharmaceutical Medicine (FFPM), and a publication record including first-author contributions in Nature Neuroscience and multiple Phase I clinical development studies.

CORE EXPERTISE

- Team Leadership & Mentorship
- Scientific & Clinical Problem-Solving
- Cross-Functional Leadership & Collaboration
- Strategic Decision-Making & Clinical Judgment
- Analytical Thinking & Data-Driven Decision-Making
- Clinical Trial Safety Oversight
- PK/PD Analysis & Interpretation
- Dose Escalation Strategy & Safety Review
- First-in-Human (FIH) Clinical Trial Leadership
- Protocol Design & Clinical Trial Feasibility Assessment

PROFESSIONAL EXPERIENCE

MEDICAL DIRECTOR & PRINCIPAL INVESTIGATOR, PHASE I CLINICAL TRIALS *2021 to Present*

Nucleus Network **Melbourne, VIC**

Appointed Medical Director of Melbourne site (2024), providing clinical and operational leadership within a leading early-phase clinical trials organization supporting global biotech and pharmaceutical sponsors.

Executive & Strategic Leadership

- Provide medical leadership across early-phase clinical programs, contributing to clinical development strategy through feasibility assessment, protocol evaluation, and sponsor engagement.
- Influence early development pathways by advising sponsors on trial design, dose-escalation frameworks, and safety considerations across diverse therapeutic programs.
- Contribute to business development and strategic feasibility initiatives, supporting evaluation of new clinical opportunities and sponsor partnerships across early development programs.

Clinical Development & Program Impact

- Principal Investigator for 70+ first-in-human studies across small molecules, biologics, siRNA, mRNA, antibodies, and vaccines.
- Lead Safety Review Committees (SRC/SMC), driving dose-escalation decisions, risk-benefit assessments, and early clinical development decision-making.
- Interpret PK/PD data and early efficacy signals to inform progression strategies and development direction.
- Contribute to translation of preclinical data into clinical strategy, including review of investigator brochures and protocol design.